O.V. Somonova1, A.L. Elizarova2, A.V. Sytov3, M.I. Timoshkov4, I.V. Babkina5, M.A. Kononov6

1–3,5,6 N.N. Blokhin National Medical Research Center of Oncology
of the Ministry of Health of the Russian Federation (Moscow, Russia)

4 G.B. Mirzoev Russian University of Advocacy and Notariate (Moscow, Russia)

1 somonova@mail.ru, 2 anna_el@rambler.ru, 3 drsytov@rambler.ru, 5 docbabkina@rambler.ru

Modern studies have shown that thromboembolic complications in cancer patients occur 7-11 times more often than in patients with other diseases and occupy one of the leading places among the causes of death. Cancer patients with thrombosis more often have distant metastases and one-year survival rate in such patients is worse than in patients without thrombosis. The leading role in the pathogenesis of thrombotic complications in patients with malignant neoplasms is played by changes in the hemostatic system caused by both the tumor itself and treatment methods. Currently, low molecular weight heparins (LMWH) are the main drugs in the prevention of thrombotic complications in cancer patients. Among all LMWHs registered on the Russian market, Fluxum polysaccharide chains are the most standardized in molecular weight (4000 to 6000 Da). Anti-Xa activity for a long time (up to 20 hours) determines the stable anticoagulation effect of Fluxum and the predictability of treatment results. The purpose of the work is to evaluate the effectiveness and safety of the use of sodium parnaparin for the prevention and treatment of thrombotic complications in cancer patients. We studied 88 patients with malignant tumors of thoracoabdominal localization. All patients received surgical treatment. Patients of group I (58 people) received 4250 IU of anti/Xa activity of sodium parnaparin (LMWH) for 7-10 days of the postoperative period. Control group (30 people) Group II – patients who did not receive drug prevention of thrombotic complications. The use of the LMWH parnaparin sodium from the 1st day of the postoperative period in cancer patients significantly reduces the intensity of intravascular coagulation. The effectiveness of the use of parnaparin sodium is evidenced by clinical data. In the group of patients who did not receive drug prophylaxis (group 2), the incidence of thrombotic postoperative complications was 4 (13.3%) cases, in the group of patients receiving sodium parnaparin (group 1) - 1 (1.7%) happening. There were no hemorrhagic complications. The use of sodium parnaparin for the prevention and treatment of thrombotic complications in the postoperative period in cancer patients has proven the high effectiveness and safety of this LMWH.

Somonova O.V., Elizarova A.L., Sytov A.V., Timoshkov M.I., Babkina I.V., Kononov M.A. Possibilities of using parnaparin sodium in oncology. Technologies of Living Systems. 2024. V. 21. № 3. Р. 45-52. DOI: https://doi.org/10.18127/j20700997-202403-05 (In Russian).

1. Levine M.N., Lee A.Y., Kakkar A.K. From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer. J. Thromb. Haemost. 2003. V. 1. № 7. P. 1456–1463. DOI: 10.1046/j.1538-7836.2003.00275.x
2. Walker A.J., Card T.R., West J. et al. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur. J. Cancer. 2013. V. 49. № 6. P. 1404–1413. DOI: 10.1016/j.ejca.2012.10.021
3. Mulder F.I., Horvath-Puho E., van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021. V. 137. № 14. P. 195–1969. DOI: 10.1182/blood.2020007338
4. Falanga A., Ay C., Di Nisio M. et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann. Oncol. 2023. V. 34. № 5. P. 452–467. DOI: 10.1016/j.annonc.2022.12.014
5. Ay C., Pabinger I., Cohen A.T. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb. Haemost. 2017. V. 117. № 2. P. 219–230. DOI: 10.1160/TH16-08-0615
6. Cohen A.T., Katholing A., Rietbrock S. et al. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb. Haemost. 2017. V. 117. № 1. P. 57–65. DOI: 10.1160/TH15-08-0686
7. Agnelli G., Verso M. Management of venous thromboembolism in patients with cancer. J. Thromb. Haemost. 2014. V. 9 (Suppl 1). P. 316–324. DOI: 10.1111/j.1538-7836.2011.04346.x
8. Barsam S.J., Patel R., Arya R. Anticoagulation for prevention and treatment of cancer-related venous thromboembolis. Br. J. Haematol. 2013. V. 161. № 6. P. 764–777. DOI: 10.1111/bjh.12314. Epub 2013 Apr 5
9. Kakkos S.K., Gohel M., Baekgaard N. et al. European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur. J. Vasc. Endovasc. Surg. 2021. V. 61. № 1. P. 9–82. DOI: 10.1016/j.ejvs.2020.09.023
10. Falanga A., Marchetti M., Vignoli A. Coagulation and cancer: biological and clinical aspects. J. Thromb. Haemost. 2013. V. 11. № 2. P. 223–233. DOI: 10.1111/jth.12075
11. Khorana A.A, Mackman N., Falanga A. et al. Cancer-associated venous thromboembolism. Nat. Rev. Dis. Primers. 2022. V. 8. № 1. P. 11. DOI: 10.1038/s41572-022-00336-y
12. Nickel K.F., Labberton L., Long A.T. et al. The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies. Thromb. Res. 2016. V. 141 (Suppl 2). P. 4–7. DOI: 10.1016/S0049-3848(16)30353-X
13. Shao B.Z., Yao Y., Li J.P. et al. The role of neutrophil extracellular traps in cancer. Front. Oncol. 2021. V. 11. Article 714357. DOI: 10.3389/fonc.2021.714357
14. Falanga A., Marchetti M. Hemostatic biomarkers in cancer progression. Thromb. Res. 2018. V. 164 (Suppl 1). P. 54–61. DOI 10.1016/j.thromres.2018.01.017
15. Cate H., Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol. Haemost. Thromb. 2007. V. 36. № 3-4. P. 122–130. DOI: 10.1159/000175150
16. Agnelii G., Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thromb. Res. 2010. V. 125(Suppl. 2). P. 17–20. DOI: 10.1016/S0049-3848(10)70007-4
17. Chew H.K., Wun T., Harvey D. et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 2006. V. 166. № 4. P. 458–464. DOI: 10.1001/archinte.166.4.458
18. Weitz J.I. Potential of new anticoagulants in patients with cancer. Thromb. Res. 2010. V. 125 (Suppl 2). P. 30–35.
19. Gran O.V., Braekhan S.K., Hansen J.B. Protrombotic genotypes and risk of venous thromboembolism in cancer. Thromb. Res. 2018.
    V. 164 (Suppl 1). P. 12–18. DOI 10.1016/j.thromres.2017.12.025
20. Woodruff S., Lee A.Y., Carrier M. et al. Low-Molecular-Weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in high- and low-risk patients with active cancer: a post hoc analysis of the CLOT Study. J. Thromb. Thrombolysis. 2019. V. 47. № 4. P. 495–504. DOI: 10.1007/s11239-019-01833-w
21. Agnelli G., Bolis G., Capussotti L. et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann. Surg. 2006. V. 243. № 1. P. 89–95. DOI: 10.1097/01.sla.0000193959.44677.48
22. Petrov V.I., Gorbatenko V.S., Shatalova O.V., Gerasimenko A.S. Venoznyye tromboembolicheskiye oslozhneniya u onkologicheskikh bolnykh: etiopatogenez i profilaktika. Lekarstvennyy vestnik. 2020. T. 14. № 3 (79). S. 16–22. (in Russian).
23. Andriyashkin V.V., Somonova O.V., Panteleyev M.A. i dr. Diagnostika. lecheniye i profilaktika tromboembolicheskikh oslozhneniy u onkologicheskikh i onkogematologicheskikh bolnykh: Ucheb. posobiye. M.: FGBOU DPO RMANPO Minzdrava Rossii. 2017. 76 s. (in Russian).
24. Falanga A., Marchetti M. Cancer-associated thrombosis: enhanced awareness and pathophysiologic complexity. J. Thromb. Haemost. 2023. V. 21. № 6. P. 1397–1408. DOI: 10.1016/j.jtha.2023.02.029
25. Somonova O.V., Antukh E.A., Vardanyan A.V. dr. Prakticheskiye rekomendatsii po profilaktike i lecheniyu tromboembolicheskikh oslozhneniy u onkologicheskikh bolnykh. Zlokachestvennyye opukholi. Prakticheskiye rekomendatsii Rossiyskogo obshchestva klinicheskoy onkologii. 2023. T. 13. № 3. S. 167–178. DOI: 10.18027/2224-5057-2023-13-3s2-167-178 (in Russian).
26. Key N.S., Khorana A.A., Kuderer N.M. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical Practice Guideline Update. J. Clin. Oncol. 2023. V. 41. Iss. 16. P. 3063–3071. DOI https://doi.org/10. 1200/JCO.23.00294
27. Farge D., Frere C., Connors J.M. et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022. V. 23. № 7. e334-e347. DOI: 10.1016/S1470-2045(22)00160-7
28. Camporese G., Bernardi E., Noventa F. Update on the clinical use of the low-molecular-weight heparin, parnaparin. Vascular Health and Risk Management. 2009. V. 5. P. 819–831. DOI: 10.2147/vhrm.s3430